RT Journal Article
T1 Potential Diagnostic Value of the Differential Expression of Histone H3 Variants between Low- and High-Grade Gliomas
A1 Hervas-Corpion, Irati
A1 Gallardo-Orihuela, Andrea
A1 Catalina-Fernandez, Inmaculada
A1 Iglesias-Lozano, Irene
A1 Soto-Torres, Olga
A1 Geribaldi-Doldan, Noelia
A1 Dominguez-Garcia, Samuel
A1 Luna-Garcia, Nuria
A1 Romero-Garcia, Raquel
A1 Mora-Lopez, Francisco
A1 Iriarte-Gahete, Marianela
A1 Morales, Jorge C.
A1 Campos-Caro, Antonio
A1 Castro, Carmen
A1 Gil-Salu, Jose L.
A1 Valor, Luis M.
K1 glioblastoma
K1 astrocytoma
K1 oligodendroglioma
K1 H3.1/H3.2
K1 H3.3
K1 H3F3B
K1 HIST1H3F
K1 HIST1H3G
K1 HIST1H3J
K1 diagnosis
K1 RNA-seq
AB In the search of the key factors that differentiate the aggressive glioblastomas from lower-grade gliomas, we determined that the variants of the structural protein of the nucleosome histone H3 show different degrees of expression. In general, high expression of H3.1/H3.2 was associated with clinical features of glioblastomas whereas high expression of H3.3 was linked to molecular alterations found in low-grade gliomas. In fact, those glioblastomas showing low expression levels of H3.1/H3.2 are highly similar to low-grade gliomas, suggesting an association with glioma aggressiveness that deserves further investigation in large cohorts. Glioblastoma (GB) is the most aggressive form of glioma and is characterized by poor prognosis and high recurrence despite intensive clinical interventions. To retrieve the key factors underlying the high malignancy of GB with potential diagnosis utility, we combined the analysis of The Cancer Gene Atlas and the REMBRANDT datasets plus a molecular examination of our own collection of surgical tumor resections. We determined a net reduction in the levels of the non-canonical histone H3 variant H3.3 in GB compared to lower-grade astrocytomas and oligodendrogliomas with a concomitant increase in the levels of the canonical histone H3 variants H3.1/H3.2. This increase can be potentially useful in the clinical diagnosis of high-grade gliomas, as evidenced by an immunohistochemistry screening of our cohort and can be at least partially explained by the induction of multiple histone genes encoding these canonical forms. Moreover, GBs showing low bulk levels of the H3.1/H3.2 proteins were more transcriptionally similar to low-grade gliomas than GBs showing high levels of H3.1/H3.2. In conclusion, this study identifies an imbalanced ratio between the H3 variants associated with glioma malignancy and molecular patterns relevant to the biology of gliomas, and proposes the examination of the H3.3 and H3.1/H3.2 levels to further refine diagnosis of low- and high-grade gliomas in future studies.
PB Mdpi
SN 2072-6694
YR 2021
FD 2021-10-20
LK https://hdl.handle.net/10668/25236
UL https://hdl.handle.net/10668/25236
LA en
NO Hervás-Corpión I, Gallardo-Orihuela A, Catalina-Fernández I, Iglesias-Lozano I, Soto-Torres O, Geribaldi-Doldan N, et al. Potential Diagnostic Value of the Differential Expression of Histone H3 Variants between Low- and High-Grade Gliomas. Cancers (Basel). 2021;13(21):5261. Published 2021 Oct 20.
NO L.M.V. is supported by Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+i and financed by Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional 2014-2020 (grants CP15/00180, PI16/00722, PI19/00125) and by Plan Propio INiBICA (grant L19-07IN-CO07). A.C.-C. is supported by Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+i and financed by Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional 2014-2020 (grant PI15/01147). C.C. is supported by Ministerio de Ciencia e Innovación (grant RTI2018-099908-B-C21) and Consejería de Economía, Conocimiento, Empresas y Universidades convocatoria de proyectos I+D+i en el marco operativo FEDER-Andalucía (grant sol-2018-00106647-tra). L.M.V. is the recipient of a Miguel Servet I contract (CP15/00180) followed by a Miguel Servet II contract (CPII20/00025), and J.C.M is the recipient of a Río Hortega contract (CM18/00043), financed by Instituto de Salud Carlos III and Fondo Social Europeo 2014-2020, Programa Estatal de Promoción del Talento y su empleabilidad en I+D+i.
DS RISalud
RD Sep 16, 2025